Navigation Links
Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc.

LOVELAND, Colo., Dec. 14, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska"), a leading provider of advanced diagnostic and specialty products to veterinarians, announced today the intent to collaborate with Entegrion Inc., a company with core expertise in blood-related disorders.  The parties are to explore unique technologies in the areas of coagulation and blood cell-based therapeutics, for use in the veterinary market.     

"Heska is pleased to announce this strategic initiative into an exciting frontier in medicine, and expand our product and service offerings," commented Michael McGinley, President and Chief Operating Officer of Heska.  "As part of Heska's stated commitment to growth, focused on the introduction of innovative and competitively differentiated products, we seek to work with innovative leaders in the life science sector.  Entegrion is just such an innovator, sharing a parallel path with us in advancing healthcare – Heska committed to advancing animal health, and Entegrion committed to identifying and developing new technologies for human medical needs. We expect this collaboration will lead to the development of products that advance our mutual goals."

Joseph DaCorta, Vice President and Chief Technology Officer for Entegrion Inc., stated "Entegrion is pleased to join forces with Heska, a veterinary industry leader, dedicated to perfecting and supporting quality pet care and whose pursuit of innovation directly matches Entegrion's values and focus on meeting unmet health needs."

About Heska

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at

About Entegrion

Entegrion is a life sciences development company that is focused on improving the safety and availability of the world's blood supply.  Based in North Carolina's Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality.  Many of Entegrion's advances in biologics are based on close collaborations with leading medical research institutions.  Visit for more information.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties including risks related to Heska's reliance on a third party, Entegrion Inc., to collaborate and deliver specific products of interest.  There are  uncertainties regarding Heska and Entegrion's ability to successfully commercialize new products; uncertainties regarding Heska's ability to market, sell and distribute products; uncertainties regarding the performance of any new products in field use; uncertainties regarding the outcome of any collaborations between Heska and any third party, including Entegrion; risks related to relying on the reputation of Heska, Entegrion or any other entity, which is subject to interpretation and may change over time; uncertainties related to the future development efforts of any third party; competition; and  the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-Q for the quarter ended September 30, 2011.

SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Announces Q309 Results
2. Heska Announces Launch of New Website
3. Heska Announces Supply Agreement With Roche Diagnostics
4. Heska Announces Extension of Credit Agreement With Wells Fargo
5. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast
6. Heska to Present at SunTrust Robinson Humphrey 1st Annual Veterinary Conference
7. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
8. Heska Announces Q310 Results
9. Heska Corporation Awards $25,000 Grand Prize to Pets Forever
10. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
11. Heska Corporation Announces Stockholder Approval of Reverse Split
Post Your Comments:
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... shareholders held today, the Company,s shareholders voted in favor ... announced agreement and plan of merger (the "Merger Agreement") ...
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, ... biologics, consumer health and global clinical supply services, today announced that Dr. Christine ... Supply East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Bolier Reactor System. Brillouin is the developer of renewable energy technologies capable of ... nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a ... of recent video interviews with some of the staff members at their recovery center. ... treatment facility, as well as some of the things that make their recovery program ...
Breaking Medicine News(10 mins):